Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

New Insights into Immunogenomics of Uveal Melanoma Revealed in Recent Study

Recent research published in Nature Communications sheds light on the immunogenomics of uveal melanoma, revealing insights that could impact the development of immunotherapies for this rare and challenging cancer.

Uveal melanoma is a type of cancer that arises from the eye, specifically the immune-privileged eye, making it particularly resistant to traditional immunotherapies. While immune checkpoint inhibition has shown promise in treating metastatic cutaneous melanoma, its efficacy against metastatic uveal melanoma has been limited.

To better understand why uveal melanoma is resistant to immunotherapy, researchers conducted a comprehensive analysis of 100 human uveal melanoma metastases. By combining clinicogenomics, transcriptomics, and assessing the potency of tumor-infiltrating lymphocytes, the study uncovered key findings.

The study revealed that more than half of the uveal melanoma metastases analyzed contained tumor-infiltrating lymphocytes with potent autologous tumor specificity, despite having a low mutational burden and showing resistance to previous immunotherapies. However, the researchers observed a low level of T cell receptor clonality within the tumor microenvironment, even after prior immunotherapy treatments.

To leverage these dormant tumor-infiltrating lymphocytes, the researchers developed a transcriptomic biomarker that could identify and release these cells ex vivo to counteract their growth suppression. Furthermore, they demonstrated that transferring these selected tumor-infiltrating lymphocytes could enhance tumor immunity in patients with metastatic uveal melanoma, especially when traditional immunotherapies have been ineffective.

This groundbreaking research provides new insights into the complexities of uveal melanoma and offers potential strategies for overcoming immunotherapy resistance in this challenging cancer type. By harnessing the power of transcriptomic biomarkers and targeted immune cell therapies, researchers may pave the way for more effective treatment options for patients with metastatic uveal melanoma.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *